Clinical dosage and effectiveness Study of ShanStar® Cranberry supplement for Prevention and Treatment against women's Urinary Tract Infections
- Conditions
- rinary tract infectionUrological and Genital DiseasesUrinary tract infection
- Registration Number
- ISRCTN55813586
- Lead Sponsor
- ShanStar Biotech, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 60
1. Age between the age of 18-50
2. Female gender
3. Healthy individual with 3 or more episodes of urinary tract infections per year
4. Able to complete the research study
1. Terminal diesease or dementia
2. Abstain from any cranberry, health food fruit extracts, anti-oxidants, vitamins, minerals and antibiotics for 2 weeks prior to participation in the study
3. Pregnancy
4. Urine catherisation within previous 2 weeks of study
5. Participants with history of diabetes, cardiovascular disease, symptoms of pyelonephritis and stones in the urinary tract
6. Sexually transmitted disease
7. Pyuria or bacteriuria on urinalysis or positive urine culture ( will be treated and wait 2 weeks to be eligible)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method At 1, 2, and 3 months, the participants will return to answer urinary tract symptoms questions and provide urine for complete urialysis and culture.<br>Primary outcome measures are:<br>1. Decrease in urinary tract infection symptoms score and decreased bacteriruia and pyuria and culture in urine study
- Secondary Outcome Measures
Name Time Method o secondary outcome measures